Nemaura Medical Inc. (NASDAQ: NMRD) Appoints Technical Healthcare Specialist Dr. Arash Ghadar as COO
- NMRD appoints UK-based Dr. Arash Ghadar as Chief Operating Officer, brings decades of healthcare and technology experience
- Dr. Ghadar previously supervised product development lifecycles, feasibility studies, prototyping, validation, quality management, volume manufacturing, certification
- NMRD commercializing sugarBEAT(R) non-invasive, flexible, CGM device, recently completed initial shipment to UK licensee MySugarWatch Limited
- MySugarWatch Limited aims to market devices via subscription-based diabetes coaching and management service
Nemaura Medical (NASDAQ: NMRD), a medical technology company developing affordable non-invasive wearable diagnostic devices and digital tools for chronic disease management, recently appointed Dr. Arash Ghadar as Chief Operating Officer (https://nnw.fm/vygSE). Dr. Ghadar brings decades of UK-based technical and healthcare management experience to Nemaura, including his current non-executive director role at Medilink Midlands – the Midlands Life Sciences industry association – where he aims to advance the Midlands life science sector.
“I am delighted to join Nemaura, a company with a world-class ambition to transform people’s lives,” said Dr. Ghadar. “I very much look forward to working with management and the wider team to successfully commercialize the transformational line of non-invasive products the company is developing, beginning with our continuous glucose monitoring devices and sensors for patients with diabetes.
Dr. Ghadar holds BSc and Masters degrees in Electronics and Control Systems Engineering and a Ph.D. in Biosensors from The University of Warwick. He brings a decade of healthcare and technical management experience to Nemaura from his previous tenure as Technical Director at Datalink Electronics. In that role, Dr. Ghadar managed daily operations, legal affairs, business planning, finance, sales, and business development of the design team. Dr. Ghadar’s also supervised numerous healthcare and industrial-related projects, including product development lifecycles, design, development, feasibility studies, prototyping, validation, quality management, volume manufacturing, and certification.
“Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations,” said Nemaura CEO Dr. Faz Chowdhury. “He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily within a contract design and manufacturing setting. That will be a true asset for the company during the commercialization phase of our growth.”
NMRD is currently commercializing its sugarBEAT(R) non-invasive, flexible, and affordable continuous glucose monitoring (“CGM”) device in the UK. The company has begun shipment of devices and sensors to MySugarWatch Limited as part of an order of 5,000 CGM devices and 200,000 sensors. Plans to market the devices include a subscription-based diabetes coaching and management service aimed at nearly 5 million diabetics and 13.6 million people at increased risk of contracting Type 2 diabetes in the UK (https://nnw.fm/KRcSf). In addition, NMRD recently launched beta trials of Miboko, its new metabolic health program for use by employers and insurers worldwide (https://nnw.fm/9ZRLP), which has started to gain strong traction. The company plan a large scale marketing campaign to grow this subscription based business.
Founded in 2011, NMRD first developed a single platform technology to measure blood markers at the skin’s surface. The company since evolved the technology to address a global need for wearable glucose-monitoring devices at the intersection of diabetes, pre-diabetes, and weight loss markets. With several filed and pending patents, along with substantial trade secrets covering its technology platform, Nemaura is positioned favorably within the rapidly growing wearable diagnostic device industry.
For more information, visit the company’s website at www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://nnw.fm/NMRD
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- NMRD appoints UK-based Dr. Arash Ghadar as Chief Operating Officer, brings decades of healthcare and technology experience
- Dr. Ghadar previously supervised product development lifecycles, feasibility studies, prototyping, validation, quality management, volume manufacturing, certification
- NMRD commercializing sugarBEAT(R) non-invasive, flexible, CGM device, recently completed initial shipment to UK licensee MySugarWatch Limited
- MySugarWatch Limited aims to market devices via subscription-based diabetes coaching and management service
Nemaura Medical (NASDAQ: NMRD), a medical technology company developing affordable non-invasive wearable diagnostic devices and digital tools for chronic disease management, recently appointed Dr. Arash Ghadar as Chief Operating Officer (https://nnw.fm/vygSE). Dr. Ghadar brings decades of UK-based technical and healthcare management experience to Nemaura, including his current non-executive director role at Medilink Midlands – the Midlands Life Sciences industry association – where he aims to advance the Midlands life science sector.
“I am delighted to join Nemaura, a company with a world-class ambition to transform people’s lives,” said Dr. Ghadar. “I very much look forward to working with management and the wider team to successfully commercialize the transformational line of non-invasive products the company is developing, beginning with our continuous glucose monitoring devices and sensors for patients with diabetes.
Dr. Ghadar holds BSc and Masters degrees in Electronics and Control Systems Engineering and a Ph.D. in Biosensors from The University of Warwick. He brings a decade of healthcare and technical management experience to Nemaura from his previous tenure as Technical Director at Datalink Electronics. In that role, Dr. Ghadar managed daily operations, legal affairs, business planning, finance, sales, and business development of the design team. Dr. Ghadar’s also supervised numerous healthcare and industrial-related projects, including product development lifecycles, design, development, feasibility studies, prototyping, validation, quality management, volume manufacturing, and certification.
“Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations,” said Nemaura CEO Dr. Faz Chowdhury. “He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily within a contract design and manufacturing setting. That will be a true asset for the company during the commercialization phase of our growth.”
NMRD is currently commercializing its sugarBEAT(R) non-invasive, flexible, and affordable continuous glucose monitoring (“CGM”) device in the UK. The company has begun shipment of devices and sensors to MySugarWatch Limited as part of an order of 5,000 CGM devices and 200,000 sensors. Plans to market the devices include a subscription-based diabetes coaching and management service aimed at nearly 5 million diabetics and 13.6 million people at increased risk of contracting Type 2 diabetes in the UK (https://nnw.fm/KRcSf). In addition, NMRD recently launched beta trials of Miboko, its new metabolic health program for use by employers and insurers worldwide (https://nnw.fm/9ZRLP), which has started to gain strong traction. The company plan a large scale marketing campaign to grow this subscription based business.
Founded in 2011, NMRD first developed a single platform technology to measure blood markers at the skin’s surface. The company since evolved the technology to address a global need for wearable glucose-monitoring devices at the intersection of diabetes, pre-diabetes, and weight loss markets. With several filed and pending patents, along with substantial trade secrets covering its technology platform, Nemaura is positioned favorably within the rapidly growing wearable diagnostic device industry.
For more information, visit the company’s website at www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://nnw.fm/NMRD
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
